Antibodies

Antibodies News

'Longer interval between COVID-19 vaccine doses generates nine times higher antibodies'
India

'Longer interval between COVID-19 vaccine doses generates nine times higher antibodies'

The finding by researchers at the UK Health Security Agency (UKHSA) also suggests that eight months after primary infection may be an optimum time to receive the first vaccine in those with prior infection.

Omicron subvarient BA.2: Here's all you need to know
World

Omicron subvarient BA.2: Here's all you need to know

Omicron is a 'highly divergent' variant which has reduced the protection of antibodies from both prior infection and vaccination, and increased transmissibility

Omicron: You may forget the COVID-19 variant but here's why your T-cells won't
India

Omicron: You may forget the COVID-19 variant but here's why your T-cells won't

The view that the immune system — prepped via either recovery from infection, or vaccination — can tackle the new variant has found support in a South African study that credits T-cells with putting up a robust defence against Omicron

Antibodies from original coronavirus strain don't bind to variants, claims study in Nature Communications journal
Health

Antibodies from original coronavirus strain don't bind to variants, claims study in Nature Communications journal

The finding, published in the journal Nature Communications, has implications for the ability of new variants to reinfect people who contracted earlier versions of the virus, as well as for the continuing efficacy of vaccines and the design of booster shots.

Over 86% of Mumbai's population have COVID-19 antibodies: BMC's latest sero-survey
India

Over 86% of Mumbai's population have COVID-19 antibodies: BMC's latest sero-survey

The survey, fifth since the onset of the pandemic, was conducted between 12 August and 9 September, 2021, the civic body said in a release.

COVID-19: ICMR’s fourth sero survey finds 67.6% of Indians over age of six have antibodies
India

COVID-19: ICMR’s fourth sero survey finds 67.6% of Indians over age of six have antibodies

A third of the population did not have SARS-CoV-2 antibodies, which means about 40 crore people are still vulnerable to COVID-19 infection, the sero survey found

Pfizer vaccine protects against COVID-19 strain predominant in India but is slightly less effective, finds study
India

Pfizer vaccine protects against COVID-19 strain predominant in India but is slightly less effective, finds study

People who received two Pfizer doses saw a three-fold reduction in their antibodies against the Indian variant.

Body produces antibodies against COVID-19 for months even after a mild infection: Study
science

Body produces antibodies against COVID-19 for months even after a mild infection: Study

In the bone marrow, these cells continually secrete low levels of antibodies into the bloodstream to help guard against the virus.

Why you should get a COVID-19 vaccine, even after you’ve recovered from coronavirus?
science

Why you should get a COVID-19 vaccine, even after you’ve recovered from coronavirus?

Not everyone develops immunity after the infection - nine percent didn't have detectable antibodies, seven percent didn't have T cells that recognize the virus.

People over the age of 65 are more likely to suffer from COVID-19 reinfections
World

People over the age of 65 are more likely to suffer from COVID-19 reinfections

While initial infection with Covid-19 is more likely to bestow 80 percent protection from reinfection to those under 65 years of age.

First baby born with COVID-19 antibodies to a woman partially-vaccinated with Moderna vaccine
science

First baby born with COVID-19 antibodies to a woman partially-vaccinated with Moderna vaccine

Antibodies from the mother’s dose of the vaccine passed through the placenta to the newborn, doctors said.

GSK, Vir Bio's COVID-19 antibody treatment can reduce hospitalisation, deaths
science

GSK, Vir Bio's COVID-19 antibody treatment can reduce hospitalisation, deaths

They announced the results of the study, pending online publication, that demonstrates the efficacy of VIR-7831 against variants of concern from the UK, South Africa and Brazil.

COVID-19 vaccine-induced antibodies less effective against some variants, finds study
World

COVID-19 vaccine-induced antibodies less effective against some variants, finds study

The study noted that the antibodies induced by the Pfizer and Moderna vaccines were less effective against the variants first described in Brazil and South Africa

The goal is herd immunity against COVID-19, when will we know if we have reached it?
science

The goal is herd immunity against COVID-19, when will we know if we have reached it?

Proof that we’re nearing herd immunity would be a “disruption in the chain of transmission.”

Scientists are working to spot new viruses before they can spread, cause future pandemics
science

Scientists are working to spot new viruses before they can spread, cause future pandemics

The human immune system keeps a record of pathogens it has met before, in the form of antibodies that fight against them and then stick around for life.

COVID-19 immunity lasts for six months, longer after infection finds new study
science

COVID-19 immunity lasts for six months, longer after infection finds new study

The immune system creates memory B cells that recognise the virus and unleash a new round of antibodies when encountered the next time.

What are monoclonal antibodies ? Why do we need them as well as a COVID-19 vaccine?
science

What are monoclonal antibodies ? Why do we need them as well as a COVID-19 vaccine?

The FDA issued emergency use authorization for Eli Lilly’s monoclonal antibody while Regeneron is still awaiting the FDA’s green light for its antibody treatment.

Quality and not quantity of antibodies suggests if one may have severe COVID-19 or die of disease
Health

Quality and not quantity of antibodies suggests if one may have severe COVID-19 or die of disease

Antibody development and neutralisation of the virus have been suggested to be some of the deciding factors that predict the outcomes of COVID-19. As a result, several studies have been conducted in the past few months to determine whether humans produce a robust immune response against SARS-CoV-2, the causative agent of novel coronavirus disease.

Childrens' immune systems make fewer antibodies against SARS-CoV-2 virus, COVID-19 study finds
science

Childrens' immune systems make fewer antibodies against SARS-CoV-2 virus, COVID-19 study finds

The findings could have implications in testing, undermining results from tests that look for antibodies to certain proteins of the virus.